LUNAR CV - Arcturus Therapeutics
Alternative Names: LUNAR-CVLatest Information Update: 28 Sep 2023
At a glance
- Originator Arcturus Therapeutics
- Class Cardiovascular therapies; RNA
- Mechanism of Action Protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (IV)
- 03 Aug 2020 LUNAR CV - Arcturus Therapeutics is available for licensing as of 03 Aug 2020. https://arcturusrx.com/business-development/